文献速递心血管技术与安全PET

心脏结节病免疫抑制治疗的前瞻性分析:PRESTIGE研究

Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation: The PRESTIGE Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2023-07-12

PRESTIGE研究前瞻性纳入59例活动性心脏结节病患者,以18F-FDG-PET心肌代谢活性(CMA)评估炎症。初始泼尼松龙治疗6个月后CMA中位数从203.3降至1.0(P<0.001)。对泼尼松龙反应不佳或复发者随机接受甲氨蝶呤或重复泼尼松龙治疗6个月,两组CMA均无显著下降,甲氨蝶呤与重复泼尼松龙疗效相当。

要点

  • 18F-FDG-PET的CMA可用于定量评估心脏结节病活动性炎症和治疗反应。
  • 初始泼尼松龙6个月治疗可显著降低CMA,但部分患者反应不佳或复发。
  • 对泼尼松龙反应不佳者,甲氨蝶呤与重复泼尼松龙6个月后CMA下降均不显著。
英文原文(摘要)· 点击展开

BACKGROUND: Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) can noninvasively assess active inflammatory myocardium in patients with cardiac sarcoidosis (CS). Prednisolone (PSL) is the initial drug of choice for active CS; however, its efficacy has not been prospectively evaluated. Moreover, there are no alternative systematic treatment strategies.

OBJECTIVES: The goal of this study was to evaluate the efficacy of methotrexate (MTX) in patients refractory to PSL assessed by using cardiac metabolic activity (CMA) in 18F-FDG-PET.

METHODS: A total of 59 patients with active CS were prospectively enrolled. CMA (standardized uptake value × accumulation area) was used as an indicator of active inflammation, and a 6-month regimen of PSL therapy was introduced, followed by a second FDG scan. Poor responders to PSL therapy (CMA reduction rate <70%) and patients with recurrent CS (CMA reduction rate ≥70% after initial PSL therapy but CMA recurred after an additional 6 months of therapy) were randomly assigned to the MTX or repeat PSL (re-PSL) therapy groups for another 6 months.

RESULTS: Fifty-six patients completed the initial 6-month PSL therapy regimen. Median CMA reduced from 203.3 to 1.0 (P < 0.001), and 47 patients were allocated to the response group, 9 to the poor response group, and 2 to the recurrent group. Accordingly, 11 patients were randomly assigned to the MTX (n = 5) or re-PSL (n = 6) groups. After 6 months, neither group showed a significant reduction in CMA values. MTX was comparable to re-PSL in reducing CMA.

CONCLUSIONS: The 6-month regimen of PSL was a potent therapeutic tool for active CS. When MTX was added to low-dose PSL in patients refractory to the initial PSL therapy, there was no significant difference compared with re-PSL. Further studies are needed to evaluate the therapeutic potential of MTX for active CS, including how MTX works when it is administered in higher doses or for longer periods.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Morimoto R, Unno K, Fujita N, et al. Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation: The PRESTIGE Study. JACC Cardiovasc Imaging. 2023. PMID: 37452820. doi:10.1016/j.jcmg.2023.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。